REG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan

HUTCHMED (China)Announcement

11/03/2026 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260311:nRSK1032Wa&default-theme=true

RNS Number : 1032W  Hutchmed (China) Limited  11 March 2026

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 11, 2026:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the
2025 annual results of HUTCHMED on March 5, 2026, the following awards granted
under the Long Term Incentive Plan ("LTIP") on June 5, 2023 to Dr Weiguo Su
and Mr Johnny Cheng were vested on March 10, 2026:-

 

 Award Holders                                                                   Number of ordinary shares
 Person Discharging Managerial Responsibilities
 Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific  524,079
 Officer)
 Mr Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief   202,238
 Financial Officer)
 Total                                                                           726,317

 

The notifications set out below are provided in accordance with the
requirements of the UK Market Abuse Regulation.

 

(a)  Dr Weiguo Su

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Dr Weiguo Su

 2    Reason for the notification

 a)   Position/status                                               Executive Director, Chief Executive Officer and Chief Scientific Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   Ordinary Shares of US$0.10

      Identification code

                                                                    Ordinary Share with DI ISIN: KYG4672N1016

 b)   Nature of the transaction                                     Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       524,079 ordinary shares

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2026-03-10

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2026-03-10

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(b)  Mr Johnny Cheng

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Mr Johnny Cheng

 2    Reason for the notification

 a)   Position/status                                               Executive Director, Acting Chief Executive Officer and Chief Financial Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   Ordinary Shares of US$0.10

      Identification code

                                                                    Ordinary Share with DI ISIN: KYG4672N1016

 b)   Nature of the transaction                                     Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       202,238 ordinary shares

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2026-03-10

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2026-03-10

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 
About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
     Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZGMFVGFGVZM



            Copyright 2019 Regulatory News Service, all rights reserved